Renaissance Technologies’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Renaissance Technologies’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-70,400	Closed	-$10.3M	–	4618
2022 Q2	$10.3M	Buy	+70,400	New	+$8.99M	0.01%	1093
2019 Q3	–	Sell	-121,800	Closed	-$5.33M	–	3918
2019 Q2	$5.33M	Buy	121,800 +116,400	+2,156%	+$6.56M	﹤0.01%	1779
2019 Q1	$278K	Buy	+5,400	New	+$233K	﹤0.01%	3117
2017 Q4	–	Sell	-14,200	Closed	-$531K	–	3687
2017 Q3	$531K	Buy	+14,200	New	+$431K	﹤0.01%	2776

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies's BHVN Position: Q3 2022 in Review

Renaissance Technologies sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 70,400 shares — an estimated $10.3M sold.

Renaissance Technologies first reported a position in BHVN in Q3 2017 and held it in 4 quarters. The position peaked at $10.3M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Renaissance Technologies reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Renaissance Technologies sold 70,400 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $10.3M.
Renaissance Technologies first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 4 quarters.
Renaissance Technologies's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $10.3M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.